Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (<i>UGT1A1</i>)
Ken Konaka(Tokushima University Hospital), Keisuke Ishizawa(Tokushima University Hospital), Masaki Imanishi(Tokushima University Hospital), Sachiko Mori(Tokushima Municipal Hospital), Tatsuhiko Saito(Tohoku University), Takumi Sakurada(Tokushima University Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Shuji Fushitani(Tokushima University Hospital)
Cited by 6
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175